Results 191 to 200 of about 59,839 (262)

Workflow-embedded automation improves hepatitis B screening and safety in b/tsDMARD users. [PDF]

BMC Infect Dis
Kuo MH, Tseng CW, Huang CW, Tseng KC, Lu MC, Tung CH, Chen NT, Huang KY, Lai NS.   +8 more
europepmc   +1 more source

Differing Epidemiology of Chronic Hepatitis C Infection, Treatment, and Outcomes Among Migrants and Australian‐Born Patients

Journal of Viral Hepatitis, Volume 33, Issue 8, August 2026.
ABSTRACT The burden of hepatitis C virus (HCV) infection often falls disproportionately on migrant populations within high‐income countries. Differences in health literacy, language, comorbidities, and HCV genotype may influence HCV natural history. 3537 persons including 652 migrants treated for HCV infection with direct‐acting antiviral (DAA) (2016 ...
Belaynew W. Taye, Patricia C. Valery, Simone I. Strasser, Martin Weltman, Alex J. Thompson, Miriam T. Levy, Barbara Leggett, Amany Zekry, Y. Julian Rong, Marie Sinclair, Jacob George, William Sievert, Gerry MacQuillan, Edmund Tse, Amanda Wade, Wendy Cheng, Stuart K. Roberts, Paul J. Clark   +17 more
wiley   +1 more source

Protein quality control and antigen presentation in the development of hepatitis B-related hepatocellular carcinoma. [PDF]

Front Pharmacol
An L, Han Y, Sun X, Wang L, Guo L.
europepmc   +1 more source

The Silent Burden of Hepatitis B‐Related Stigma

Journal of Viral Hepatitis, Volume 33, Issue 8, August 2026.
ABSTRACT Individuals experiencing stigma related to chronic hepatitis B virus (HBV) infection often experience negative self‐beliefs, isolation, discrimination, and reduced willingness to engage with healthcare professionals. We aimed to understand the patient perspective of HBV‐related stigma and to summarize the patient experience of stigma in a ...
Verity Smith, Menita Asriah, Katherine Fernelius, Joyeta Das, Laura Grant, Vera Gielen, Shannon Keith   +6 more
wiley   +1 more source

Clinical significance and mutation analysis of HBsAg and Anti-HBs coexistence in Chronic Hepatitis B. [PDF]

Virus Res
Zhang S, Lai X, Dai H, Li X, Li X, Liu F, Zhou T, Wei J.   +7 more
europepmc   +1 more source

Trends in Hepatitis B, Hepatitis C, and HIV Seroprevalence in the Netherlands: Insights From Two Decades of Nationwide PIENTER Serosurveys

Journal of Viral Hepatitis, Volume 33, Issue 8, August 2026.
ABSTRACT Hepatitis B (HBV), hepatitis C (HCV), and HIV remain public health challenges despite effective treatments and preventive options. Infections are often asymptomatic, leading to undiagnosed cases, onward transmission, and preventable morbidity and mortality.
Christine G. J. I. van Straten, Birgit H. B. van Benthem, Fiona R. M. van der Klis, Gaby Smits, Eric R. A. Vos, Tom Woudenberg, Marc van der Valk, Eline L. M. Op de Coul   +7 more
wiley   +1 more source

Optimization of a Target Antigen Diagnostic Pathway for Membranous Nephropathy. [PDF]

Kidney Int Rep
Li W, Huang C, Yue S, Rao Q, Qin X, Hu H, Wang L, Cen J, Xu R, Song H, Xu Y, Zhang X, Wang X, Dong X, Cheng Y, Wan Q.   +15 more
europepmc   +1 more source

Prevention of HBV Mother‐To‐Child Transmission (MTCT) Using Targeted HBV Birth Dose, and Treatment of High Viral Load Pregnant Women in Uganda

Journal of Viral Hepatitis, Volume 33, Issue 8, August 2026.
ABSTRACT Hepatitis B virus (HBV) mother‐to‐child transmission (MTCT) remains a major challenge in Uganda, where 43% of births occur at home, and access to timely birth dose (BD) vaccination is limited. We evaluated the impact of combining universal three‐dose (3D) infant vaccination, targeted BD vaccination, and maternal antiviral treatment for high ...
Samantha Hall, Ponsiano Ocama, Danielle Leavelle, Julius Kiwanuka, Brian Lwanga, Joan Nankya‐Mutyoba, Calvin Q. Pan, Christine Namulindwa, Viola Kasone, Rachel Beyagira, Homie Razavi   +10 more
wiley   +1 more source

Bacterial Membrane Vesicles as Versatile Platforms for Systemic and Mucosal Vaccines. [PDF]

Vaccines (Basel)
Park SH, Son YM.
europepmc   +1 more source

From Diagnosis to Durability: A Review of the European Bulevirtide Experience and Practical Learnings for CHD Management

Liver International, Volume 46, Issue 8, August 2026.
ABSTRACT Hepatitis delta virus (HDV) infection causes chronic hepatitis D (CHD), the most severe form of chronic viral hepatitis with a high risk of progression to advanced liver disease. Off‐label pegylated interferon alpha was the primary treatment option in Europe prior to the introduction of bulevirtide, a first‐in‐class HDV entry inhibitor.
Monica Radu, Margarita Papatheodoridi, Habiba Kamal Khodir, Sabela Lens, Elisabetta Degasperi, Speranta Iacob, Liliana Gheorghe, Katja Steppich, Florin Alexandru Caruntu, Pietro Lampertico, Soo Aleman, Heiner Wedemeyer   +11 more
wiley   +1 more source